GC Genome Corporation (KOSDAQ:340450)

GC Genome Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	9,083	6,528	3,637	13,637	10,743	9,404
Short-Term Investments	-	-	5,000	4,000	15,000	20,000
Cash & Short-Term Investments	9,083	6,528	8,637	17,637	25,743	29,404
Cash Growth	-64.72%	-24.42%	-51.03%	-31.49%	-12.45%	624.53%
Accounts Receivable	5,101	5,439	4,307	4,221	3,702	1,604
Other Receivables	28.33	12.94	65.78	325.42	71	22.76
Receivables	5,129	5,452	4,373	4,546	3,773	1,627
Inventory	1,420	1,219	1,152	1,200	598.2	-
Prepaid Expenses	321.02	371.57	292.15	697.09	126.16	384.8
Other Current Assets	74.61	93.33	96.29	40.37	30.69	0
Total Current Assets	16,027	13,663	14,550	24,120	30,271	31,416
Property, Plant & Equipment	14,318	14,918	18,759	18,094	8,293	6,642
Long-Term Investments	7,807	7,823	6,103	3,231	1,648	1,928
Other Intangible Assets	508.58	526.09	533.37	577.52	617.6	608.61
Long-Term Accounts Receivable	-0	0	-0	0	0	-
Long-Term Deferred Tax Assets	867.6	634.11	680.04	163.81	-	55.9
Other Long-Term Assets	3,072	3,058	2,194	2,709	1,601	1,197
Total Assets	42,600	40,622	42,819	48,896	42,431	41,848
Accounts Payable	1,343	-	851.58	1,311	1,293	-
Accrued Expenses	933.9	109.91	840.06	1,830	1,185	1,234
Short-Term Debt	-	-	6,556	-	-	-
Current Portion of Leases	834.6	792.17	802.31	997.42	685.06	351.85
Current Income Taxes Payable	-	-	-	-	-	30.98
Current Unearned Revenue	1,487	1,503	941.6	1,218	1,065	434.33
Other Current Liabilities	427.18	794.57	2,986	5,036	485.16	434.69
Total Current Liabilities	5,026	3,199	12,978	10,393	4,714	2,485
Long-Term Debt	-	-	-	5,819	12,913	11,462
Long-Term Leases	3,720	3,878	4,398	3,787	508.18	551.67
Long-Term Deferred Tax Liabilities	-	-	-	-	9	-
Other Long-Term Liabilities	477.83	465.2	395.84	2,312	5,320	8,645
Total Liabilities	9,223	7,543	17,772	22,311	23,464	23,196
Common Stock	9,778	9,778	9,067	9,067	8,000	8,000
Additional Paid-In Capital	29,890	29,890	21,036	21,010	10,475	10,475
Retained Earnings	-4,984	-5,281	-3,964	-3,244	491.96	-6.54
Comprehensive Income & Other	-1,307	-1,307	-1,091	-247.95	-	184.08
Shareholders' Equity	33,377	33,080	25,048	26,585	18,967	18,652
Total Liabilities & Equity	42,600	40,622	42,819	48,896	42,431	41,848
Total Debt	4,554	4,670	11,757	10,604	14,106	12,365
Net Cash (Debt)	4,528	1,857	-3,120	7,033	11,636	17,039
Net Cash Growth	-61.08%	-	-	-39.56%	-31.71%	1449.35%
Net Cash Per Share	242.42	101.96	-170.15	435.45	727.46	955.99
Filing Date Shares Outstanding	19.78	18.22	18.34	16.15	16	17.82
Total Common Shares Outstanding	19.78	18.22	18.34	16.15	16	17.82
Working Capital	11,001	10,464	1,572	13,728	25,557	28,930
Book Value Per Share	1687.04	1815.96	1366.01	1646.07	1185.74	1046.53
Tangible Book Value	32,868	32,554	24,514	26,008	18,349	18,044
Tangible Book Value Per Share	1661.34	1787.08	1336.92	1610.31	1147.13	1012.38
Buildings	4,723	7,142	7,727	6,810	1,111	609
Machinery	4,986	12,814	13,055	11,332	9,800	7,550
Construction In Progress	-	-	-	77.14	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.